Oruka Therapeutics COO Sells Shares
Sandler Laura Lee sold 600 shares of Oruka Therapeutics valued at $41,814.
Key Points
- On June 15, 2026, Oruka Therapeutics' COO Sandler Laura Lee sold 600 shares, valued at $41,814.
- Oruka Therapeutics' stock is trading near $69.89 with a market cap of $4.22 billion and a 52-week high of $91.00.
- Analysts maintain a strong buy consensus with a mean price target of $142.17 for Oruka Therapeutics.
On June 15, 2026, Sandler Laura Lee, the Chief Operating Officer of Oruka Therapeutics, Inc. (NASDAQ: ORKA), sold 600 shares of the company's stock. The shares were sold at an average price of $69.69, amounting to a total transaction value of $41,814. This insider sale was not part of a pre-arranged trading plan.
Insider Buying and Selling at Oruka Therapeutics, Inc.
In addition to Sandler Laura Lee's sale, there was notable insider activity at Oruka Therapeutics on the same day. Joana Goncalves, the Chief Medical Officer, purchased 7,000 shares at $7.32 each and sold 3,500 shares with no price disclosed. Arjun Agarwal, Senior Vice President of Finance, sold 395 shares at $69.69, as part of a planned transaction. Paul Quinlan, General Counsel, also sold 733 shares at the same price.
Other Institutional Activity in Oruka Therapeutics
Several institutional investors have been active in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, bringing its total to 7,431,403 shares valued at about $364.5 million. Paradigm BioCapital Advisors LP made a significant increase, adding 610,000 shares to total 2,320,316 shares worth approximately $113.8 million. On the other hand, BlackRock, Inc. reduced its stake by 12,328 shares, now holding 3,527,087 shares valued at around $173 million.
Oruka Therapeutics Stock Snapshot
Shares of Oruka Therapeutics are currently trading near $69.89. The company boasts a market capitalization of approximately $4.22 billion. It has a 52-week high of $91.00 and a low of $10.77. The stock's 50-day moving average is $63.70, while the 200-day moving average is $37.60. Oruka Therapeutics has a healthy current ratio of 23.76 and a debt-to-equity ratio of 0.37, though it is not yet profitable, reflected in its negative forward P/E ratio of -28.39.
Analysts Set New Price Targets
Analysts continue to show strong support for Oruka Therapeutics. On May 14, 2026, BTIG reiterated its 'buy' rating with a price target of $151. HC Wainwright & Co. maintained its 'buy' rating on April 29, 2026, with a target of $120. Other firms like UBS and Barclays also upheld their 'buy' ratings with targets of $100 and $160, respectively. Overall, the consensus is a 'strong buy' with a mean target price of $142.17 based on 12 analyst opinions.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. It focuses on developing innovative monoclonal antibody treatments for psoriasis and other inflammatory diseases. The company's lead products include ORKA-001 and ORKA-002, targeting specific interleukins for psoriasis and psoriatic arthritis. Under the leadership of CEO Dr. Lawrence Otto Klein, Oruka continues to advance its pipeline of therapeutics in the biotechnology sector.
Bottom Line
Sandler Laura Lee's recent sale of Oruka Therapeutics shares is part of a broader pattern of insider activity at the company. Investors often keep an eye on such transactions for insights, although they don't necessarily signal a negative outlook. Oruka's stock performance and strong analyst support indicate continued interest in its potential, despite the backward-looking nature of these disclosures.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.